Related Experiment Video
Updated: Jul 5, 2025
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer
Christos Damaskos1,2, Iason Psilopatis3, Anna Garmpi4
1Renal Transplantation Unit, Laiko General Hospital, 11527 Athens, Greece.
Background/Aim:
Triple negative breast cancer belongs to the most aggressive breast cancer forms. Histone deacetylases (HDACs) constitute a class of enzymes that exhibit a significant role in breast cancer genesis and progression. In this study, we aimed at assessing the clinical importance of HDAC-2 in triple negative breast cancer.
Materials And Methods:
A total of 138 breast cancer specimens were examined on an immunohistochemical basis. A statistical analysis was performed in order to examine the association between HDAC-2 and the survival and clinicopathological features of the patients.
Results:
Increased HDAC-2 expression was observed in every fourth case of triple negative breast cancer with positive HDAC-2 staining, whereas only 12 out of 98 non-triple negative breast cancer samples showed high HDAC-2 expression. HDAC-2 overexpression correlated with prolonged overall survival (OS) and disease-free survival (DFS) in triple negative breast cancer.
Conclusions:
High HDAC-2 levels in triple negative breast cancer seem to positively influence patient survival, disease stage and recurrence.
